Dangerous liaisons between beta-amyloid and cholinergic neurotransmission

Current Pharmaceutical Design

Volumn 20, Issue 15, 2014, Pages 2525-2538

  Govoni, Stefano ^a   Mura, Elisa ^a   Preda, Stefania ^a   Racchi, Marco ^a   Lanni, Cristina ^a   Grilli, Massimo ^b   Zappettini, Stefania ^b   Salamone, Alessia ^b   Olivero, Guendalina ^b   Pittaluga, Anna ^b   Marchi, Mario ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Alzheimer's disease; Beta amyloid; Cholinergic neurotransmission; Neurotransmitters; Nicotinic receptors

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ASPARTIC ACID; CHOLINERGIC RECEPTOR; DOPAMINE; EXCITATORY AMINO ACID; GLUTAMIC ACID; GLYCINE; NICOTINE; NICOTINIC RECEPTOR; ACETYLCHOLINE; CHOLINESTERASE;

ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC STIMULATION; CHOLINERGIC SYNAPSE; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; CORPUS STRIATUM; HIPPOCAMPUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL MEMBRANE STEADY POTENTIAL; NEUROMODULATION; NEUROPATHOLOGY; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEUS ACCUMBENS; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN TARGETING; RECEPTOR BINDING; RECEPTOR UPREGULATION; REGULATORY MECHANISM; ANIMAL; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; SECRETION (PROCESS); SYNAPTIC TRANSMISSION;

ACETYLCHOLINE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CHOLINESTERASES; GAMMA-AMINOBUTYRIC ACID; HUMANS; RECEPTORS, NICOTINIC; SYNAPTIC TRANSMISSION;

EID: 84903714027     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990503     Document Type: Article

References (135)

1. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362-81.
2. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 2011; 17: 1060-5.
3. Citron M. Alzheimer's disease: strategies for disease modification. Nature Rev Drug Discov 2010; 9: 387-98.
4. Gasparini L, Racchi M, Binetti G, et al. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease. FASEB J 1998; 12: 17-34.
5. Salomone S, Caraci F, Leggio GM, et al. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol 2012; 73: 504-17.
6. Kadir A, Almkvist O, Forsberg A, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging 2012; 33: 198. e1-14.
7. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
8. Kadir A, Almkvist O, Wall A, Långström B, Nordberg A. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl) 2006; 188: 509-20.
9. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-23.
10. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. London: National Institute for Health and Clinical Excellence 2011. [NICE technology appraisal guidance 217, review of NICE technology appraisal guidance 111].
11. Mayeux R. Clinical practice. Early Alzheimer's disease. N Engl J Med 2010; 362: 2194-201.
12. Sabbagh M, Cummings J. Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol 2011; 11: 21.
13. Raschetti R, Albanese E, Vanacore N, et al. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007; 4: e338.
14. Giacobini E. Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatry 2003; 18(Suppl 1): S1-5.
15. Nordberg A, Lundqvist H, Hartvig P, et al. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains-in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 1995; 9: 21-7.
16. Perry E, Ziabreva I, Perry R, et al. Absence of cholinergic deficits in "pure" vascular dementia. Neurology 2005; 64: 132-3.
17. Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009; 73: 273-8.
18. Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012; 3: CD006504.
19. Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006; 66: 17-22.
20. Allard S, Leon WC, Pakavathkumar P, Bruno MA, Ribeiro-da-Silva A, Cuello AC. Impact of the NGF maturation and degradation pathway on the cortical cholinergic system phenotype. J Neurosci 2012; 32: 2002-12.
21. Cuello AC, Bruno MA, Allard S, Leon W, Iulita MF. Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation. J Mol Neurosci 2010; 40: 230-5.
22. Bruno MA, Leon WC, Fragoso G, Mushynski WE, Almazan G, Cuello AC. Amyloid beta-induced nerve growth factor dysmetabolism in Alzheimer disease. J Neuropathol Exp Neurol 2009; 68: 857-69.
23. Buoso E, Lanni C, Schettini G, et al. Beta-Amyloid precursor protein metabolism: focus on the functions and degradation of its intracellular domain. Pharmacol Res 2010; 62: 308-17.
24. Buoso E, Biundo F, Lanni C, et al. A. PP intracellular C-terminal domain function is related to its degradation processes. J Alzheimers Dis 2012; 30: 393-405.
25. Schettini G, Govoni S, Racchi M, et al. Phosphorylation of APPCTF-AICD domains and interaction with adaptor proteins: signal transduction and/or transcriptional role--relevance for Alzheimer pathology. J Neurochem 2010; 115: 1299-308.
26. Westman E, Spenger C, Oberg J, et al. In vivo 1H-magnetic resonance spectroscopy can detect metabolic changes in APP/PS1 mice after donepezil treatment. BMC Neurosci 2009; 10: 33.
27. Racchi M, Sironi M, Caprera A, et al. Short-and long-term effect of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein. Mol Psychiatry 2001; 6: 520-8.
28. Racchi M, Mazzucchelli M, Porrello E, et al. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 2004; 50: 441-51.
29. Racchi M, Govoni S. Rationalizing a pharmacological intervention on the amyloid precursor protein metabolism. Trends Pharmacol Sci 1999; 20: 418-23.
30. Racchi M, Govoni S. The pharmacology of amyloid precursor protein processing. Exp Gerontol 2003; 38: 145-57.
31. Lenzken SC, Lanni C, Govoni S, et al. Nicotinic component of galantamine in the regulation of amyloid precursor protein processing. Chem Biol Interact 2007; 165: 138-45.
32. Zimmermann M, Borroni B, Cattabeni F, et al. Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol Dis 2005; 19: 237-42.
33. Fisher A. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. J Neurochem 2012; 120(Suppl 1): 22-33.
34. Nitsch RM, Slack BE, Wurtman RJ, et al. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258: 304-7.
35. Buxbaum JD, Oishi M, Chen HI, et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci USA 1992; 89: 10075-8.
36. Pittel Z, Heldman E, Barg J, et al. Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum. Brain Res 1996; 742: 299-304.
37. Nitsch RM, Kim C, Growdon JH. Vasopressin and bradykinin regulate secretory processing of the amyloid protein precursor of Alzheimer's disease. Neurochem Res 1998; 23: 807-14.
38. Davis-Salinas J, Saporito-Irwin SM, Donovan FM, et al. Thrombin receptor activation induces secretion and nonamyloidogenic processing of amyloid beta-protein precursor. J Biol Chem 1994; 269: 22623-7.
39. Lee RK, Wurtman RJ, Cox AJ, et al. Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc Natl Acad Sci USA 1995; 92: 8083-7.
40. Nitsch RM, Deng M, Growdon JH, et al. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem 1996; 271: 4188-94.
41. Mills J, Reiner PB. Regulation of amyloid precursor protein cleavage. J Neurochem 1999; 72: 443-60.
42. Davis AA, Fritz JJ, Wess J, et al. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J Neurosci 2010; 30: 4190-6.
43. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010; 9: 702-16.
44. Kim SH, Kim YK, Jeong SJ, et al. Enhanced Release of Secreted Form of Alzheimer's Amyloid Precursor Protein from PC12 Cells by Nicotine. Mol Pharmacol 1997; 52: 430-6.
45. Takata K, Kitamura Y, Saeki M, et al. Galantamine-induced amyloid-{ beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem 2010; 285: 40180-91.
46. Nie H, Li Z, Lukas RJ, et al. Construction of SH-EP1-alpha4beta2-hAPP695 cell line and effects of nicotinic agonists on beta-amyloid in the cells. Cell Mol Neurobiol 2008; 28: 103-12.
47. Mousavi M, Hellström-Lindahl E. Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro. Neurochem Int 2009; 54: 237-44.
48. Tong M, Arora K, White MM, et al. Role of key aromatic residues in the ligand-binding domain of alpha7 nicotinic receptors in the agonist action of beta-amyloid. J Biol Chem 2011; 286: 34373-81.
49. Parri HR, Hernandez CM, Dineley KT. Research update: Alpha 7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease. Biochem Pharmacol 2011; 82: 931-42.
50. Buckingham SD, Jones AK, Brown LA, et al. Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev 2009; 61: 39-61.
51. Mura E, Lanni C, Preda S, et al. Beta-amyloid: a disease target or a synaptic regulator affecting age-related neurotransmitter changes? Curr Pharm Des 2010; 16: 672-83.
52. Puzzo D, Privitera L, Leznik E, et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 2008; 28: 14537-45.
53. Puzzo D, Privitera L, Fa' M, et al. Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 2011; 69: 819-30.
54. Kuo YM, Emmerling MR, Vigo-Pelfrey C, et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 1996; 271: 4077-81.
55. Naslund J, Schierhorn A, Hellman U, et al. Relative abundance of Alzheimer Abeta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA 1994; 91: 8378-82.
56. Bao F, Wicklund L, Lacor PN, et al. Different.-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging 2012; 33: 825. e1-13.
57. Ni R, Marutle A, Nordberg A. Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer's disease brain. J Alzheimers Dis 2013; 33: 841-51.
58. Kadir A, Marutle A, Gonzalez D, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain 2011; 134(Pt 1): 301-17.
59. Hellström-Lindahl E, Mousavi M, Ravid R, Nordberg A. Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer's patients. Neurobiol Dis 2004; 15: 351-60.
60. Hellström-Lindahl E, Court J, Keverne J, et al. Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. Eur J Neurosci 2004; 19: 2703-10.
61. Feuerbach D, Lingenhoehl K, Olpe HR, et al. The selective nicotinic acetylcholine receptor [alpha] 7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology 2009; 56: 254-63.
62. Marrero MB, Papke RL, Bhatti BS, Shaw S, Bencherif M. The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo [3,2,2] nonane (TC-1698), a novel alpha 7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase. J Pharmacol Exp Ther 2004; 309: 16-27.
63. Boess FG, De Vry J, Erb C, et al. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 2007; 321: 716-25.
64. Li SF, Wu MN, Wang XH, et al. Requirement of t7 nicotinic acetylcholine receptors for amyloid ß protein-induced depression of hippocampal long-term potentiation in CA1 region of rats in vivo. Synapse 2011; 65: 1136-43.
65. Foster ER, Campbell MC, Burack MA, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010; 25: 2516-23.
66. Zhong P, Gu Z, Wang X, et al. Impaired modulation of GABAergic transmission by muscarinic receptors in a mouse transgenic model of Alzheimer's disease. J Biol Chem 2003; 278: 26888-96.
67. Preda S, Govoni S, Lanni C, et al. Acute beta amyloid administration disrupts the cholinergic control of dopamine release in the nucleus accumbens. Neuropsychopharmacology 2008; 33: 1062-70.
68. Liu W, Dou F, Feng J, et al. RACK1 is involved in beta-amyloid impairment of muscarinic regulation of GABAergic transmission. Neurobiol Aging 2011; 32: 1818-26.
69. Akaike A. Preclinical evidence of neuroprotection by cholinesterase inhibitors. Alzheimer Dis Assoc Disord 2006; 20(2 Suppl 1): S8-11.
70. Fishman EB, Siek GC, MacCallum RD, et al. Distribution of the molecular forms of acetylcholinesterase in human brain: alterations in dementia of the Alzheimer type. Ann Neurol 1986; 19: 246-52.
71. Davis KL, Mohs RC, Marin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer's disease. JAMA 1999; 281: 1401-6.
72. Perry RH, Blessed G, Perry EK, et al. Histochemical observations on cholinesterase activities in the brains of elderly normal and demented (Alzheimer-type) patients. Age Ageing 1980; 9: 9-16.
73. Ulrich J, Meier-Ruge W, Probst A, et al. Senile plaques: staining for acetylcholinesterase and A4 protein: a comparative study in the hippocampus and entorhinal cortex. Acta Neuropathol 1990; 80: 624-8.
74. Inestrosa NC, Dinamarca MC, Alvarez A. Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. FEBS J 2008; 275: 625-32.
75. Inestrosa NC, Urra S, Colombres M. Acetylcholinesterase (AChE)--amyloid-beta-peptide complexes in Alzheimer's disease. The Wnt signaling pathway. Curr Alzheimer Res 2004; 1: 249-54.
76. Rees T, Hammond PI, Soreq H, et al. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol Aging 2003; 24: 777-87.
77. Sberna G, Sáez-Valero J, Beyreuther K, et al. The amyloid betaprotein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. J Neurochem 1997; 69: 1177-84.
78. Chauhan NB, Siegel GJ. Antisense inhibition at the beta-secretasesite of beta-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576. Neuroscience 2007; 146: 143-51.
79. Bourne Y, Taylor P, Bougis PE, et al. Crystal structure of mouse acetylcholinesterase. A peripheral site-occluding loop in a tetrameric assembly. J Biol Chem 1999; 274: 2963-70.
80. Fodero LR, Mok SS, Losic D, et al. Alpha7-nicotinic acetylcholine receptors mediate an Abeta(1-42)-induced increase in the level of acetylcholinesterase in primary cortical neurones. J Neurochem 2004; 88: 1186-93.
81. Silveyra MX, Evin G, Montenegro MF, et al. Presenilin 1 interacts with acetylcholinesterase and alters its enzymatic activity and glycosylation. Mol Cell Biol 2008; 28: 2908-19.
82. Silveyra MX, García-Ayllón MS, Serra-Basante C, et al. Changes in acetylcholinesterase expression are associated with altered presenilin-1 levels. Neurobiol Aging 2012; 33: 627. e27-37.
83. McKay BE, Placzek AN, Dani JA. Regulation of Synaptic Transmission and Plasticity by Neuronal Nicotinic Acetylcholine Receptors. Biochem Pharmacol 2007; 74: 1120-33.
84. Yakel JL. Nicotinic ACh Receptors in the Hippocampus: Role in Excitability and Plasticity. Nicotine Tob Res 2012; 14: 1249-57.
85. Grilli M, Lagomarsino F, Zappettini S, et al. Specific inhibitory effect of amyloid-beta on presynaptic muscarinic receptor subtypes modulating neurotransmitter release in the rat nucleus accumbens. Neuroscience 2010; 167: 482-9.
86. Grilli M, Zappettini S, Raiteri L, et al. Nicotinic and muscarinic cholinergic receptors coexist on GABAergic nerve endings in the mouse striatum and interact in modulating GABA release. Neuropharmacology 2009; 56: 610-4.
87. Jürgensen S, Ferreira ST. Nicotinic receptors, amyloid-beta, and synaptic failure in Alzheimer's disease. J Mol Neurosci 2010; 40: 221-9.
88. Mura E, Preda S, Govoni S, et al. Specific neuromodulatory actions of amyloid-beta on dopamine release in rat nucleus accumbens and caudate putamen. J Alzheimers Dis 2010; 19: 1041-53.
89. Ondrejcak T, Klyubin I, Hu NW, et al Alzheimer's disease amyloid beta-protein and synaptic function. Neuromolecular Med 2010; 12: 13-26.
90. Mura E, Zappettini S, Preda S, et al. Dual effect of beta-amyloid on alpha 7 and alpha 4 beta 2 nicotinic receptors controlling the release of glutamate, aspartate and GABA in rat hippocampus. PLoS One 2012; 7: e29661.
91. Zappettini S, Grilli M, Olivero G, et al. Beta Amyloid Differently Modulate Nicotinic and Muscarinic Receptor Subtypes which Stimulate in vitro and in vivo the Release of Glycine in the Rat Hippocampus. Front Pharmacol 2012; 3: 146.
92. Khan GM, Tong M, Jhun M, et al. Beta-Amyloid activates presynaptic alpha7 nicotinic acetylcholine receptors reconstituted into a model nerve cell system: involvement of lipid rafts. Eur J Neurosci 2010; 31: 788-96.
93. Liu Q, Kawai H, Berg DK. Beta-Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA 2001; 98: 4734-9.
94. Wang HY, Bakshi K, Shen C, et al. S 24795 limits beta-amyloidalpha7 nicotinic receptor interaction and reduces Alzheimer's disease-like pathologies. Biol Psychiatry 2010; 67: 522-30.
95. Lilja AM, Porras O, Storelli E, et al. Functional interactions of fibrillar and oligomeric amyloid-β with alpha7 nicotinic receptors in Alzheimer's disease. J Alzheimers Dis 2011; 23: 335-47.
96. Welsby PJ, Rowan MJ, Anwyl R. Beta-amyloid blocks high frequency stimulation induced LTP but not nicotine enhanced LTP. Neuropharmacology 2007; 53: 188-95.
97. Srivareerat M, Tran TT, Salim S, et al. Chronic nicotine restores normal Aβ levels and prevents short-term memory and E-LTP impairment in Aβ rat model of Alzheimer's disease. Neurobiol Aging 2011; 32: 834-44.
98. Mehta TK, Dougherty JJ, Wu J, et al. Defining pre-synaptic nicotinic receptors regulated by beta amyloid in mouse cortex and hippocampus with receptor null mutants. J Neurochem 2009; 109: 1452-8.
99. Pandya A, Yakel JL. Allosteric modulator Desformylflustrabromine relieves the inhibition of α2β2 and α4β2 nicotinic acetylcholine receptors by β-amyloid(1-42) peptide. J Mol Neurosci 2011; 45: 42-7.
100. Pettit DL, Shao Z, Yakel JL. Beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 2001; 21: RC120.
101. Wu J, Khan GM, Nichols RA. Dopamine release in prefrontal cortex in response to beta-amyloid activation of alpha7 * nicotinic receptors. Brain Res 2007; 1182: 82-9.
102. Trabace L, Kendrick KM, Castrignanò S, et al. Soluble amyloid beta1-42 reduces dopamine levels in rat prefrontal cortex: relationship to nitric oxide. Neuroscience 2007; 147: 652-63.
103. McQuiston AR, Madison DV. Nicotinic receptor activation excites distinct subtypes of interneurons in the rat hippocampus. J Neurosci 1999; 19: 2887-96.
104. Sudweeks SN, Yakel JL. Functional and molecular characterization of neuronal nicotinic ACh receptors in rat CA1 hippocampal neurons. J Physiol 2000; 527(Pt 3): 515-28.
105. Yakel JL, Shao Z. Functional and molecular characterization of neuronal nicotinic ACh receptors in rat hippocampal interneurons. Prog Brain Res 2004; 145: 95-107.
106. Picciotto MR, Zoli M, Léna C, et al. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 1995; 374: 65-7.
107. Levin ED, Simon BB. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 1998; 138: 217-30.
108. Wang HY, Lee DH, Davis CB, et al. Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem 2000; 75: 1155-61.
109. Raiteri L, Raiteri M. Synaptosomes still viable after 25 years of superfusion. Neurochem Res 2000; 25: 1265-74.
110. Lee DH, Wang HY. Differential physiologic responses of alpha7 nicotinic acetylcholine receptors to beta-amyloid1-40 and betaamyloid1-42. J Neurobiol 2003; 55: 25-30.
111. Kar S, Seto D, Gaudreau P, et al. Beta-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices. J Neurosci 1996; 16: 1034-40.
112. Zappettini S, Grilli M, Salamone A, et al. Pre-synaptic nicotinic receptors evoke endogenous glutamate and aspartate release from hippocampal synaptosomes by way of distinct coupling mechanisms. Br J Pharmacol 2010; 161: 1161-71.
113. Zappettini S, Grilli M, Lagomarsino F, et al. Presynaptic nicotinic a7 and non-a7 receptors stimulate endogenous GABA release from rat hippocampal synaptosomes through two mechanisms of action. PLoS One 2011; 6: e16911.
114. Dickinson JA, Kew JN, Wonnacott S. Presynaptic alpha 7-and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. Mol Pharmacol 2008; 74: 348-59.
115. Ida N, Hartmann T, Pantel J, et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 1996; 271: 22908-14.
116. Brody DL, Magnoni S, Schwetye KE, et al. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 2008; 321: 1221-4.
117. Alvira-Botero X, Carro EM. Clearance of amyloid-ß peptide across the choroid plexus in Alzheimer's disease. Curr Aging Sci 2010; 3: 219-29.
118. Serot JM, Zmudka J, Jouanny P. A possible role for CSF turnover and choroid plexus in the pathogenesis of late onset alzheimer's disease. J Alzheimers Dis 2012; 30: 17-26.
119. Dineley KT, Bell KA, Bui D, et al. Beta-Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 2002; 277: 25056-61.
120. Wu M, Hajszan T, Leranth C, et al. Nicotine recruits a local glutamatergic circuit to excite septohippocampal GABAergic neurons. Eur J Neurosci 2003; 18: 1155-68.
121. Zappettini S, Mura E, Grilli M, et al. Different presynaptic nicotinic receptor subtypes modulate in vivo and in vitro the release of glycine in the rat hippocampus. Neurochem Int 2011; 59: 729-38.
122. Mori M, Gähwiler BH, Gerber U. Beta-alanine and taurine as endogenous agonists at glycine receptors in rat hippocampus in vitro. J Physiol 2002; 539(Pt 1): 191-200.
123. Petrini EM, Marchionni I, Zacchi P, et al. Clustering of extrasynaptic GABA(A) receptors modulates tonic inhibition in cultured hippocampal neurons. J Biol Chem 2004; 279: 45833-43.
124. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci 2005; 6: 215-29.
125. Baker AJ, Zornow MH, Scheller MS, et al. Changes in extracellular concentrations of glutamate, aspartate, glycine, dopamine, serotonin, and dopamine metabolites after transient global ischemia in the rabbit brain. J Neurochem 1991; 57: 1370-9.
126. Saransaari P, Oja SS, Borkowska HD, et al. Effects of thioacetamide-induced hepatic failure on the N-methyl-D-aspartate receptor complex in the rat cerebral cortex, striatum, and hippocampus. Binding of different ligands and expression of receptor subunit mRNAs. Mol Chem Neuropathol 1997; 32: 179-93.
127. Saransaari P, Oja SS. Effects of inhibitory amino acids on adenosine release in the mouse hippocampus. Proc West Pharmacol Soc 2008; 51: 15-7.
128. Zhao P, Qian H, Xia Y. GABA and glycine are protective to mature but toxic to immature rat cortical neurons under hypoxia. Eur J Neurosci 2005; 22: 289-300.
129. Gill JK, Savolainen M, Young GT, et al. Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci USA 2011; 108: 5867-72.
130. Gill JK, Dhankher P, Sheppard TD, et al. A Series of β7 Nicotinic Acetylcholine Receptor Allosteric Modulators with Close Chemical Similarity but Diverse Pharmacological Properties. Mol Pharmacol 2012; 81: 710-8.
131. Young GT, Zwart R, Walker AS, et al. Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci USA 2008; 105: 14686-91.
132. Magdesian MH, Nery AA, Martins AH, et al. Peptide blockers of the inhibition of neuronal nicotinic acetylcholine receptors by amyloid beta. J Biol Chem 2005; 280: 31085-90.
133. Small DH, Maksel D, Kerr ML, et al. The beta-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the a7 nicotinic acetylcholine receptor. J Neurochem 2007; 101: 1527-38.
134. Saavedra L, Mohamed A, Ma V, et al. Internalization of betaamyloid peptide by primary neurons in the absence of apolipoprotein E. J Biol Chem 2007; 282: 35722-32.
135. Boyd-Kimball D, Castegna A, Sultana R, et al. Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res 2005; 1044: 206-15.